Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
After nearly one year of its use, omaveloxolone (RTA 408) significantly improved neurological function across several clinical measures in people with Friedreich’s ataxia (FA), and was generally safe and ... Read more
The natural antioxidant epicatechin significantly improves heart structure and function in young people with Friedreich’s ataxia (FA) over nearly six months of treatment, a small Phase 2 study has ... Read more
Endurance exercise prevented the onset of symptoms without the need to restore frataxin production in a mouse model of Friedreich’s ataxia (FA), a study shows, potentially paving the way for ... Read more
SNH6, a new dual-action therapy, has the potential to restore mitochondria function and may ultimately be used to treat cardiomyopathy in patients with Friedreich’s ataxia (FA), a mouse study ... Read more
Symptoms of depression significantly affect the quality of life of people with Friedreich’s ataxia (FA), a study has found. The study, “Health-related quality of life and depressive symptoms in ... Read more